EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prognostic factors in first-line atezolizumab-bevacizumab treatment of intermediate or advanced hepatocellular carcinoma

Kyowon Gu iD, Tae Wook Kang iD, Jaeseung Shin, Dong Hyun Sinn, Myung Ji Goh, Jung Yong Hong, Sangah Chi

PLOS One · 28.07.2026 · 21 (7) · e0354176

DOI: 10.1371/journal.pone.0354176 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, online erschienen am 28.07.2026. Verfasst von Kyowon Gu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology and Center for Imaging Science, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Liver Neoplasms, Carcinoma, Hepatocellular, Antibodies, Monoclonal, Humanized, Bevacizumab. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To analyze the prognostic factors influencing outcomes in hepatocellular carcinoma (HCC) patients initially treated with atezolizumab-bevacizumab (Ate-Bev).

Methods

We conducted a retrospective study on 47 treatment-naïve HCC patients (40 men; median age, 56 years) who were treated with Ate-Bev between September 2020 and July 2022 and underwent at least one response assessment based on the Response Evaluation Criteria in Solid Tumors 1.1. We evaluated the clinical variables and imaging features of pre-treatment magnetic resonance imaging (MRI). Using multivariable Cox hazard regression analysis, we analyzed prognostic factors for progression-free survival (PFS).

Results

During the follow-up period (range, 1.5–24.9 months), 33 patients (70.2%) experienced tumor progression. The median PFS was 4.3 months (95% confidence interval [CI], 2.8–8.5 months). Nine patients received concomitant radiotherapy. Multivariable analysis indicated that younger age (hazard ratio [HR], 0.95; 95% CI, 0.92–0.99; P = 0.013), absence of concomitant radiation therapy (HR, 0.22; 95% CI, 0.07–0.69; P = 0.009), tumor extent ≥10 cm (HR, 2.54; 95% CI, 1.17–5.55; P = 0.019), and peritumoral arterial-phase hyperenhancement on the MRI (HR, 2.15; 95% CI, 1.00–4.63; P = 0.049) were factors associated with poor PFS.

Conclusions

Age, concomitant radiation therapy, tumor extent, and peritumoral arterial-phase hyperenhancement on MRI were associated with PFS in patients with HCC who were initially treated with Ate-Bev.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver NeoplasmsCarcinoma, HepatocellularAntibodies, Monoclonal, HumanizedBevacizumabAntineoplastic Combined Chemotherapy ProtocolsHumansMiddle AgedMaleRetrospective StudiesFemalePrognosisAgedAdultMagnetic Resonance ImagingProgression-Free Survival

Substanzen

Antibodies, Monoclonal, HumanizedatezolizumabBevacizumab

Autor:innen und Institutionen

  • Department of Radiology and Center for Imaging Science, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
  • Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
  • Statistics and Data Center, Research Institute for Future Medicine, Samsung Medical Center, Republic of Korea.

ORCID-Profile: Kyowon Gu, Tae Wook Kang

Zitieren

APA

Gu, K., Kang, T. W., Shin, J., Sinn, D. H., Goh, M. J., Hong, J. Y., & Chi, S. (2026). Prognostic factors in first-line atezolizumab-bevacizumab treatment of intermediate or advanced hepatocellular carcinoma. PLOS One, 21(7), e0354176. https://doi.org/10.1371/journal.pone.0354176

Vancouver

Gu K, Kang TW, Shin J, Sinn DH, Goh MJ, Hong JY, et al. Prognostic factors in first-line atezolizumab-bevacizumab treatment of intermediate or advanced hepatocellular carcinoma. PLOS One. 2026;21(7):e0354176. doi:10.1371/journal.pone.0354176

BibTeX
@article{Gu2026,
  author = {Gu, Kyowon and Kang, Tae Wook and Shin, Jaeseung and Sinn, Dong Hyun and Goh, Myung Ji and Hong, Jung Yong and Chi, Sangah},
  title = {Prognostic factors in first-line atezolizumab-bevacizumab treatment of intermediate or advanced hepatocellular carcinoma},
  journal = {PLOS One},
  year = {2026},
  volume = {21},
  number = {7},
  pages = {e0354176},
  doi = {10.1371/journal.pone.0354176}
}
Kostenlos starten →